The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Istanbul Medeniyet University

Status: Unknown

Conditions: Non-Invasive Bladder Urothelial Carcinoma; Bladder Cancer Recurrent

Study type: Observational

Funder types: Other

Identifiers

NCT04617743

IMU Urology

Details and patient eligibility

About

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Full description

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. Participants who underwent transurethral resection for bladder tumor will be included in the study. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with transitional cell non-muscle invasive bladder cancer (NMIBC) pathology
• Patients with a diagnosis of Bladder cancer (NMIBC)
• Patients undergoing transurethral resection for bladder cancer (NMIBC)
• ≥18 years old patients

Exclusion criteria

• Non-transitional cell bladder cancers
• Patients with muscle-invasive bladder cancer pathology
• <18 years old patients

Trial design

500 participants in 2 patient groups

High residual volume

Description:

Bladder tumor patients with high residual volume

Low residual volume

Description:

Bladder tumor patients with low residual volume